Randomized, double-blind, parallel group, placebo-controlled, dose finding study in colorectal cancer patients receiving 5-FU-based chemotherapy to assess the efficacy of different doses of s.c. elsiglutide in the prevention of Chemotherapy Induced Diarrhea (CID)

Trial Profile

Randomized, double-blind, parallel group, placebo-controlled, dose finding study in colorectal cancer patients receiving 5-FU-based chemotherapy to assess the efficacy of different doses of s.c. elsiglutide in the prevention of Chemotherapy Induced Diarrhea (CID)

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Elsiglutide (Primary)
  • Indications Diarrhoea
  • Focus Therapeutic Use
  • Sponsors Helsinn
  • Most Recent Events

    • 06 Jun 2017 Planned locations also included Poland as per European Clinical Trials Database.
    • 02 Jun 2017 Results (n=484) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 01 Apr 2017 Results assessing safety and efficacy published in the Trial Registry
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top